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Summary: Most material used for control and calibration in a clinical laboratory is based on pool sera of
human origin, guaranteed to be HBsAg-free. Since little Information is available on the potential infectivity
of HIV, the causative agent of acquired immunodeficiency syndrome (AIDS), 54 control and calibration
sera, in routine use, were investigated for the incidence of antibodies to HIV by means of Elisa. Sixteen test
specimens (= 30%) gave positive or borderline Elisa results and were further analysed by immunoblotting,
resulting in 15 samples all recognizing gp 160 and partially the p 24, p 31, p 55, p 64 and gp 120 band. Only
one sample with borderline Elisa result was negative by this assay. Furthermore, all sera were examined for
the presence of viral antigen by a solid phase Elisa. All samples under investigation gave negative antigen
Elisa results. Bearing in miiid that the sensitivity of this assay is limited to 10 g/l of viral antigen, no
conclusion on infectivity should be drawn. The high incidence of HlV-antibodies in the sera investigated
demands that this material should be handled with special care by laboratory personnel.
Introduction
The acquired immunodeficiency syndrome (AIDS)
(1) is a rather recently described disease primarily
affecting certain risk groups like promiscuous homo-
sexuals, drug addicts and haemöphiliacs who have
received clotting concentrates, which have not been
tested for HlV-antibödies or inactivated by heat,
and the sexual partners of these groups (2—4). The
causative agent has been described äs a human retro-
virus designated Human T lyjnphotrqpic vifus type
III/lymphadenopathy associated virus (HTLV III/
LAV) (5, 6); in the new nomenclature it is called
human immunodeficiency virus (HIV). All available
evidence suggests that transmission of the virus oc-
curs predominantly through contact with blood äs
well äs blood derivates. However, the virus has also
been isolated from other body flüids like urine or
saliva of infected persons (7).
Health workers and laboratory staff are caring for
an increasing number of patients, infected with HIV,
and there is concera regarding their risk of infection
from casual or percutaneous occasional exposure to
the virus (8, 9). In spite of a low transmission rate
of HIV infection documented within this group of
persons (10, 11), the continuation of precautions re-
garding the handling of body flüids is recommended
and emphasized. Therefore in Austria all specimens
for laboratory investigations that are suspected to
come from HIV-positive individuals have to be
marked yellow/red, for handling with special care by
laboratory staff.
For control and calibration purposes materials from
human sources are generally preferred, in order to
maintain the same matrix äs the test specimen of
interest. For this purpose most vendors provide pre-
parations tested for HBsAg, to minimize the potential
risk of hepatitis B infection. Only partial Information
is available on the incidence of antibodies to HIV in
quality assurance sera routinely used in laboratories
and their potential risk of HIV transmission. There-
fore all contrpl and calibration sera used in this
laboratory were investigated for antibodies to HIV
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by an enzyme linked inumunosorbent assay (Elisa).
Since testing for anti HIV antibodies by Elisa may
give false positives, screening results have to be con-
firmed by immunoblot analysis. Because reactivity in
these assays indicates antibody presence, but not viral
infectivity, all sera were tested for the evidence of
viral particles using an HIV antigen Elisa.
Materials and Methods
Quality assurance reagents
A total of 54 quality assurance reagents were obtained from
the following companies:
- Abbott Laboratories, North Chicago, USA (n = 15),
— American Monitor Corp. Indianapolis, USA (n = 4),
— Beckman Instruments Inc., Brea, LA, USA (n = 5),
- Behringwerke, Marburg, FRG (n = 5),
- RAD Laboratories, Richmond, LA, USA (n = 3),
— Boehringer Mannheim Diagnostics Inc., Mannheim, FRG
(n = H),
— Du Pont de Nemours Inc., Wilmington, USA (n = 5),
— Helena Laboratories, Beaumont, Texas, USA (n = 1),
- Hoffmann La Röche, Basel, Switzerland (n = 1),
— Immuno Ä\3, Vienna, Austria (n = 2),
- Merck, Darmstadt, FRG (n = 2),
— Merz -h Dade, Düdingen, Switzerland (n = 2).
Elisa screening for anti HIV antibodies
All control sera and calibrators listed above were investigated
by use of a Du Pont HIV Elisa kit (Du Pont). The assay
was performed according to the manufacturers instructions. o-
Phenylene-diamine was used äs the chromogenic Substrate, and
absorbance (A) was read at 410 nm using a Dynatec Elisa
reader within two hours after stopping the peroxidase reaction.
All samples were tested in duplicate.
The cut off for reactivity was that recommended by the manu-
facturer, calculated äs the mean absorbance of the positive
controls divided by two (experiment 1: 0.680 A, experiment
2: 0.445 A), all values above were considered to be positive.
Following the recommendations of the Paul Ehrlich Institute
(Frankfurt, FRG), this ränge was extended, and all samples
with absorbance values down to 50% beneath the suggested
cut off (exp. 1: 0.340 A, exp. 2: 0.223 A) were also examined
by the immunoblot technique.
Immunoblot analysis ' f
All positive or borderline positive Elisa results were further
investigated using an enzyme linked immuno electrotransfer
western blot kit (Du Pont). Briefly, transblotted nitrocelhilose
Strips were incubated overnight with the test samples diluted
l: 100. Detection of anti HIV antibodies was perforaied with
biotinylated anti human IgG H -f L antibodies, follöwed by a
further incubation Step with an avidin-peroxidase conjugate. 2-
Chloro-1-naphthpl was used äs the chromogen, giving a purple-
blue reaction product.
Detection of HIV viral antigen
For the demonstration of HIV Viral antigen, a sandwich solid
phase enzyme immuno assay (Abbott) was performed, follow-
ing the manufacturers instructions. The chromogenic Substrate
for the peroxidase reaction was 0-phenylene-diamine. The cut
off for reactivity was calculated by adding 0.050 to the mean
absorbance value of the three negative contfols äs recom-
mended by the manufactürer. All samples were tested in dupli-
cate and absorbance values equal to or greater than the calcu-
lated cut off value were considered reactive for HIV antigen.
Results
In this study a total fo 54 control sera and calibrators
was tested for anti HIV antibody by means of Elisa.
Sixteen sera (= 30%) gave positive or borderline
positive Elisa results (experiment l, cut off 0.680 A,
extended ränge 0.340 A, experiment 2, cut off
0.445 A, extended ränge 0.222 A). Thirty eight sera
Tab. l. Quality assurance sera with positive Elisa results by Du Pont HIV Elisa.
Manufacturer or
distributor
Lot Measured
(A)
Cut off
(A)
Lane no. in
fig. l
Beckman
Beckman
Beckman
Behring
Decision Level I
Decision Level II
Decision Level III
Kontrollogen LP
C506105
C506107
C506106
62321 OF
0.478
0.380
0.607
1.373
0.340
0.340
0.340
0.222
7
14
17
11
Bio-Rad
Bio-Rad
Boehringer
Boehringer
Boehringer
Boehringer
Boehringer
Boehringer
Merz + Dade
Merz -h Dade
Am. Monitor
Am. Monitor
Lyphocheck II
Lyphocheck III
Precinorm U
Precipath Ü
Precipath U
Precinorm U
Calibrator
Calibratpr
Moni-trol IE
Moni-trol IIE
Qualify I
Qualify II
C-370-5 11802
C-370-5 11803
151621-09
15080103-09
15294601-35
15033803-06
15352702,09
15557303-11
L -f- D 207
P -h D 107
QN21D
QA30C
0.675
0.910
0.977
0.890
0.677
1.592
1.050
0.232
0.420
0.755
0.584
0.454
0.340
0.340
0.340
0.340-
0.340
0.340
0.340
0.222
0.340
0.340
0.340
0.340
18
13
10
12
4
6
15
19
'
:
' 5
9
16
8
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(= 70%) were considered nonreactive. Two of the 38
Elisa negative samples were equine-based but supple-
mented with human material. Absorbance values for
positive reactive samples are shown in table l, for
nonreactive samples in table 2.
All these 16 positive or borderline positive Elisa re-
sults were further analysed by immunoblot. The re-
sults are demonstrated in figure 1. Lane l shows a
negative control, lanes 2 and 20 positive controls,
and lane 3 a weak reactive control sample. Lanes 4
to 19 show the 15 samples found to be Elisa-positive.
The sera that were reactive in immunoblotting experi-
ments can be identified in table l according to their
lane number indicated in figure 1. Only one sample
giving a borderline Elisa result (0.232 A, cut off
0.222 A) was negative by immunoblot analysis (lane
19). All positive samples reacted strongly with the gp
160 band. Furthermore a weaker reactivity with p 24,
p 55 and p 64 was observed. A considerable number
of samples showed an additional p 31 band (lanes
4-6, 9, 10, 12, 13, 14, 15). All control sera and
calibrators initially tested were further investigated
for HIV viral antigen using the Abbott enzyme im-
muno assay, giving negative results for all test speci-
men. To investigate the sensitivity of this assay, viral
antigen (Du Pont) was titrated from concentrations
of 20 μg/l down to 5 μ§/1. The lowest detectable
concentration of viral antigen by this assay was 10
Mg/1 (we fig. 2).
Tab. 2. Quality assurance sera with negative Elisa results.
Manufacturer or
distributor
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Abbott
Am. Monitor
Am. Monitor
Behring
Behring
Behring
Behring
Bio-Rad
Boehringer
Boehringer
Bpehringer
Boehringer
Boehringer
Du Pont
Du Pont
Du Pont
Du Pont "
Du Pont
Helena Lab.
R che
Immuno
Immuno
Merck
Merck
Phenytoin H
Phenytoin M
Phenytoin L
Phenobarbital H
Phenobarbital M
Phenobarbital L
Digitoxin H
Digitoxin M
Digitoxin L
Digoxin H
Digoxin M
Digoxin L
Methotrexate H
Methotrexate M
Methotrexate L
Standard 1
Standard 2
iSft Protein Kontr.
Pathoplasma I
Pathoplasma II
Kpntrollplasma N
Lyphocheck I
Plasmacontr. Plus
Precinorm I
Preciclpt I
Preciclot II
Precichrom II
Bilirubin Calibr. 1
Bilirubin Calibn 2
Bilirubin Calibr. 3
ACA Normal
ACA Elevated
CK/LC Isoencyme Ko
Control Serum P
Konroll PL AK-D
Kontroll PL AK-R
Seronorm TM
Pathonorm L
Lot
9507-10 83-1 07AZ
9507-10 83-107AZ
 %
9507-10 83-107AZ
9500-10 90-288 AZ
9500-10 90-288 AZ
9500-10 90-288AZ
9535-10 86-659AZ
9535-10 86-659AZ
9535-10 86-659AZ
9511-10 87-353AZ
9511-10 87-353AZ
9511-10 87-353AZ
9522-10 88-091SV
9522-10 88-091SV
9522-10 88-091SV
SL 1022 C
SH 1033 B
06 5118
502848 A
502942 A
502788 C
C 370-5 11801
175927/5269
152287
615382
615382
152419
01 1251 A
01125 1B
01125 IC
6DB621
6DB626
5131
B06379705
AK 082
AK 080
211025/74
212123/20
Measured
(A)
0.103
0.084
0.072
0.065
0.060
0.064
0.064
0.070
0.070
0.075
0.074
0.074
0.067
0.064
0.080
0.004
0.005
0.065
0.050
0.055
0.056
0.170
0.050
0.010
0.012
0.005
0.006
0.002
0.003
0.003
0.002
0.003
0.012
0.004
0.025
0.020
0.004
0.003
Cut off
(A)
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.340
0.222
0.222
0.222
0.222
0.222
0.222
0.222
0.222
0.222
0.340
0.340
0.222
0.222
0.222
0.222
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Fig. l. Immunoblot reactivity of control and calibration sera
tested in HIV antibody Elisa:
lane 1: negative control,
lanes 2, 20: positive control,
lane 3: weak positive control,
lanes 4—19: samples tested;
Individual samples may be identified in tab. 1.
Discussion
For quality assurance sera originating from human
material, the number of donors may be 6000 or more.
Although pools are tested for HBsAg, donors are
often members of risk groups for HIV infection.
Therefore 54 control sera and calibrators routinely
used in this laboratory were tested for aiitibodies to
HIV. Elisa screening gave about 30% reactive sam-
ples. These data are in agreement with Howanitz et
al. (12), who reported the presence of HIV antibodies
in about 31% of quality assurance sera on the basis
of initial tests. However, 7 of 45 reactive samples in
this study were nonreactive on repeated testing. In
our study, 15 of the 16 positive or borderline Elisa
results were confirmed by immunoblot analysis, indi-
cating that the observed Elisa reactivity was not due
to preparation artefacts. The one sample giving a
negative immunoblot result had also shown absor-
bance values close to the extended cut off value. The
fact that gp 41 could only be found in two of the 15
positively reactive sera investigated may be due to
the dilution effect, since all these quality assurance
materials are produced from pool sera, and this band
is weaker than the others even in strongly positive
cases. However, gp 160, which is known to be the -
Antibody
gp160-
gp120-
s "''*"" a*
P15/17-
Lane 1 2 3
ti
Ö
P
4-18 19 20
Fig. 2. Titration of viral antigen: cut off for sensitivity of the
assay is §/1 viral antigen. Absorbance without viral
antigen 0.057.
viral protein to which the highest titers of antibodies
are mounted, gave the strongest reactivity in all sam-
ples. Moreover, all 54 samples were tested for viral
antigen, but no positivity was observed. However,
titratiön of viral antigen using this Elisa procedure
showed sensitivity down tö concentrations of 10 §
antigen per l diluent only. Therefore no conclusions
can be drawn regarding the infectivity of the samples
tested, because the amount of infectious agent may
be beneath the quäntities detectable by the antigen
Elisa.
In high percentages of haemophiliacs receiving eom-
mercial clotting concentrates which have not been
tested for anti-HIV antibodies and heat inactivated,
transmission of the virus has been described, resulting
in the development of antibodies to HIV and exacer-
bation of AIDS (13, 14, 15). HIV has been isolated
from peripheral blood and other body fluids of most
patients with pre-AIDS, and from a considerable
number of patients with the fully developed picture
of AIDS. The virus has been isolated from lyophilized
factor VIII concentrates (16), indicating that the virus
is resistant to the lyophilization procedure.
These results strengthen the case for h.andling all
control sera with special care, and according to the
safety precautions against hepatitis B infection,
which will also protect against HIV infection (17).
Since methods are now available for testing sera for
the presence of aiiti HIV antibodies, and, further-
inore, rather mild procedures for inactivating the
virus have been established (18), vendors shoüld be
obliged to provide control and calibration materials
which are anti HIV antibody-üegative, in order to
lower the potential risk for laboratory personnel.
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